RGNX REGENXBIO Inc.

20.05
0  -2%
Previous Close 20.45
Open 20.30
Price To book 3.35
Market Cap 531.59M
Shares 26,513,000
Volume 610,678
Short Ratio 8.21
Av. Daily Volume 211,330

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 dosing initiated - March 8, 2017. Interim data due by the end of 2017.
RGX-501
Homozygous familial hypercholesterolemia (HoFH)
Phase 1/2 enrollment to be initiated 2H 2017.
RGX-111
Mucopolysaccharidosis Type I (MPS I)

Latest News

  1. REGENXBIO INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  2. Regenxbio Leads Biotech Movers Ahead of Market's Open
  3. Regenxbio Sinks After Announcing Secondary Offering
  4. 3:43 am REGENXBIO prices offering of 3.7 mln shares of common stock at $20.50 per share
  5. REGENXBIO Announces Pricing of Public Offering of Common Stock
  6. REGENXBIO Announces Proposed Public Offering of Common Stock
  7. REGENXBIO INC. Financials
  8. 6 Stocks Trending Up With Big Volume
  9. REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017
  10. Regenxbio reports 4Q loss
  11. Regenxbio reports 4Q loss
  12. Regenxbio Inc Earnings Call scheduled for 4:30 pm ET today
  13. REGENXBIO INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  14. REGENXBIO Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights
  15. REGENXBIO Announces Initiation of Phase I/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia
  16. Q4 2016 Regenxbio Inc Earnings Release - Before Market Open
  17. REGENXBIO to Present at the Cowen and Company 37th Annual Health Care Conference
  18. REGENXBIO Honors Rare Disease Day® 2017
  19. REGENXBIO to Host Conference Call on March 7 to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights
  20. Rockville gene therapy company to begin trials for treatment for leading cause of blindness